296 related articles for article (PubMed ID: 28205022)
1. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
[TBL] [Abstract][Full Text] [Related]
2. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
3. Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour.
Cahir C; Dombrowski SU; Kelly CM; Kennedy MJ; Bennett K; Sharp L
Support Care Cancer; 2015 Nov; 23(11):3115-30. PubMed ID: 25744290
[TBL] [Abstract][Full Text] [Related]
4. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
5. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
6. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
[TBL] [Abstract][Full Text] [Related]
7. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory.
AlOmeir O; Patel N; Donyai P
Support Care Cancer; 2020 Nov; 28(11):5075-5084. PubMed ID: 32601852
[TBL] [Abstract][Full Text] [Related]
8. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
[TBL] [Abstract][Full Text] [Related]
9. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Chen J; Mao JJ
Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
11. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
Wells KJ; Pan TM; Vázquez-Otero C; Ung D; Ustjanauskas AE; Muñoz D; Laronga C; Roetzheim RG; Goldenstein M; Carrizosa C; Nuhaily S; Johnson K; Norton M; Sims E; Quinn GP
Support Care Cancer; 2016 Oct; 24(10):4123-30. PubMed ID: 27146492
[TBL] [Abstract][Full Text] [Related]
12. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
14. The challenges of assessing patients' medication beliefs: a qualitative study.
Thorneloe RJ; Griffiths CE; Ashcroft DM; Cordingley L
BMC Health Serv Res; 2017 Feb; 17(1):119. PubMed ID: 28173867
[TBL] [Abstract][Full Text] [Related]
15. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
16. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
17. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
18. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
19. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).
Bluethmann SM; Alfano CM; Clapp JD; Luta G; Small BJ; Hurria A; Cohen HJ; Sugarman S; B Muss H; Isaacs C; Mandelblatt JS
Breast Cancer Res Treat; 2017 Oct; 165(3):677-686. PubMed ID: 28653250
[TBL] [Abstract][Full Text] [Related]
20. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians.
Huiart L; Ferdynus C; Giorgi R
Breast Cancer Res Treat; 2013 Feb; 138(1):325-8. PubMed ID: 23400580
[No Abstract] [Full Text] [Related]
[Next] [New Search]